EA201992136A1 - Антитела против pd-l1 - Google Patents

Антитела против pd-l1

Info

Publication number
EA201992136A1
EA201992136A1 EA201992136A EA201992136A EA201992136A1 EA 201992136 A1 EA201992136 A1 EA 201992136A1 EA 201992136 A EA201992136 A EA 201992136A EA 201992136 A EA201992136 A EA 201992136A EA 201992136 A1 EA201992136 A1 EA 201992136A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
binding
human
relates
antibodies against
Prior art date
Application number
EA201992136A
Other languages
English (en)
Inventor
Изил Алтинтас
Давид Сатейн
Эдвард Ван Ден Бринк
Деннис Верзейл
Рик Радемакер
Пауль Паррен
Барт Де Гуэй
Original Assignee
Генмаб А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Генмаб А/С filed Critical Генмаб А/С
Priority claimed from PCT/EP2018/055977 external-priority patent/WO2018162749A1/en
Publication of EA201992136A1 publication Critical patent/EA201992136A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение касается новых антител и их применения в медицине. В частности, изобретение касается биспецифичных антител, способных связываться с PD-L1 человека и способных связываться с CD3 человека. Также представлены новые классы антител, способных связываться с PD-L1 человека. Изобретение также касается применения антител по изобретению и способов, конструкций из нуклеиновых кислот и клеток-хозяев для получения антител по изобретению.
EA201992136A 2017-07-11 2018-03-09 Антитела против pd-l1 EA201992136A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201700408 2017-07-11
PCT/EP2018/055977 WO2018162749A1 (en) 2017-03-09 2018-03-09 Antibodies against pd-l1

Publications (1)

Publication Number Publication Date
EA201992136A1 true EA201992136A1 (ru) 2020-02-18

Family

ID=69636708

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992136A EA201992136A1 (ru) 2017-07-11 2018-03-09 Антитела против pd-l1

Country Status (1)

Country Link
EA (1) EA201992136A1 (ru)

Similar Documents

Publication Publication Date Title
ZA201905822B (en) Antibodies against pd-l1
MX2020001198A (es) Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CL2018003136A1 (es) Proteínas de unión específica y usos de las mismas.
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
MD3551660T2 (ro) Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
MX2021011696A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
PH12019500571A1 (en) Anti-pd-1 antibodies
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
AR115389A1 (es) Anticuerpo antagonista de cd73
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
EA201792193A1 (ru) Конструкции биспецифического антитела для cdh3 и cd3
CY1122214T1 (el) Αντισωματα ειδικα για ton fcrn
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
EA201892774A1 (ru) Антитела
EA201992206A1 (ru) Моноклональное антитело к pd-l1
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA201992136A1 (ru) Антитела против pd-l1